

## Claims

1. A method for treating a vascular disorder in a mammal, which comprises administering to a mucosal surface of said mammal an effective amount of a composition comprising at least one agent selected from the group consisting of a heat shock protein, a therapeutically effective fragment of a heat shock protein, and a therapeutically effective analog of a heat shock protein, wherein the effective amount is sufficient to treat the disorder.
2. The method of claim 1 wherein said mucosal surface comprises nasal epithelium.
3. The method of claim 1 wherein said mucosal surface comprises oral mucosa.
4. The method of claim 1 wherein said mucosal surface comprises a luminal surface of a gastrointestinal organ selected from the group consisting of: stomach, small intestine, large intestine, and rectum.
5. The method of claim 1 wherein said disorder comprises a cell-mediated immune response.
6. The method of claim 1 wherein said disorder comprises an antibody-mediated immune response.
7. The method of claim 1 wherein said disorder is atherosclerosis.
8. The method of claim 1 wherein said heat shock protein is HSP65.
9. The method of claim 1 wherein said heat shock protein is human HSP60.
10. The method of claim 1 wherein said heat shock protein is chlamydial HSP60.
11. A method for treating a vascular disorder in a mammal, which comprises administering to said mammal by inhalation an effective amount of a composition comprising at least one

agent selected from the group consisting of a heat shock protein, a therapeutically effective fragment of a heat shock protein, and a therapeutically effective analog of a heat shock protein, wherein the effective amount is sufficient to treat the disorder.

5 12. The method of claim 11 wherein said disorder comprises a cell-mediated immune response.

13. The method of claim 11 wherein said disorder comprises an antibody-mediated immune response.

10 14. The method of claim 11 wherein said disorder is atherosclerosis.

15. The method of claim 11 wherein said heat shock protein is HSP65.

15 16. The method of claim 11 wherein said heat shock protein is human HSP60.

17. The method of claim 11 wherein said heat shock protein is chlamydial HSP60.

18. The method of claim 11 wherein said agent is in aerosol form.

20 19. A method for suppressing a vascular disorder in a mammal, which comprises administering to said mammal via the pulmonary tract an effective amount of at least one agent selected from the group consisting of a heat shock protein, a therapeutically effective fragment of a heat shock protein, and a therapeutically effective analog of a heat shock protein, wherein the effective amount is sufficient to treat the disorder.

20. The method of claim 19 wherein said disorder is atherosclerosis.

21. The method of claim 19 wherein said heat shock protein is HSP65.

30 22. The method of claim 19 wherein said heat shock protein is human HSP60.

23. The method of claim 19 wherein said heat shock protein is chlamydial HSP60.

24. The method of claim 19 wherein said agent is in aerosol form.

25. A method for suppressing a cell-mediated inflammatory disorder in a mammal, which  
5 comprises discharging into the pulmonary tract of said mammal an effective amount of a  
composition comprising at least one agent selected from the group consisting of a heat  
shock protein, a therapeutically effective fragment of a heat shock protein, and a  
therapeutically effective analog of a heat shock protein, wherein the effective amount is  
sufficient to treat the disorder.

26. The method of claim 25 wherein said disorder is atherosclerosis.

27. The method of claim 25 wherein said heat shock protein is HSP65.

28. The method of claim 25 wherein said heat shock protein is human HSP60.

29. The method of claim 25 wherein said heat shock protein is chlamydial HSP60.

30. The method of claim 25 wherein said agent is in aerosol form.

31. A method for treating a vascular disorder in a mammal, which comprises orally or  
enterally administering to said mammal an effective amount of a composition comprising  
at least one agent selected from the group consisting of a heat shock protein, a  
therapeutically effective fragment of a heat shock protein, and a therapeutically effective  
25 analog of a heat shock protein, wherein the effective amount is sufficient to treat the  
disorder.

32. The method of claim 31 wherein said disorder comprises a cell-mediated immune  
response.

33. The method of claim 31 wherein said disorder comprises an antibody-mediated immune  
response.

34. The method of claim 31 wherein said disorder is atherosclerosis.

35. The method of claim 31 wherein said heat shock protein is HSP65.

5 36. The method of claim 31 wherein said heat shock protein is human HSP60.

37. The method of claim 31 wherein said heat shock protein is chlamydial HSP60.

38. The method of claim 31 wherein said composition is administered orally.

10

39. The method of claim 31 wherein said composition is administered enterally.

40. The method of claim 31 comprising administering said composition in solid form.

15 41. The method of claim 31 comprising administering said composition in semi-solid form.

42. The method of claim 31 comprising administering said composition in liquid form.

20

43. The method of claim 31 wherein said composition further comprises a pharmaceutically acceptable carrier.

25

44. A composition for treating a vascular disorder in a mammal, which comprises administering at least one agent selected from the group consisting of a heat shock protein, a therapeutically effective fragment of a heat shock protein, and a therapeutically effective analog of a heat shock protein, wherein the effective amount is sufficient to treat the disorder.

30

45. The composition of claim 44 wherein said disorder comprises a cell-mediated autoimmune response.

46. The composition of claim 44 wherein said disorder comprises an antibody-mediated autoimmune response.

47. The composition of claim 44 wherein said disorder is atherosclerosis.

48. The composition of claim 44 wherein said heat shock protein is HSP65.

5 49. The composition of claim 44 wherein said heat shock protein is human HSP60.

50. The composition of claim 44 wherein said heat shock protein is chlamydial HSP60.

51. The composition of claim 44 wherein said composition is in solid form.

10

52. The composition of claim 44 wherein said composition is in semi-solid form.

53. The composition of claim 44 wherein said composition is in liquid form.

15

54. The composition of claim 44 wherein said composition is in aerosol form.

55. The composition of claim 44 wherein said composition further comprises a  
pharmaceutically acceptable carrier.